Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Herpes Zoster
Interventions
Live attenuated herpes zoster vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney
Interventions
Post-transplant Grazoprevir and Elbasvir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Kidney Injury, Kidney Failure, Kidney Failure, Chronic, Kidney Failure, Acute, Kidney Diseases, Kidney Transplant Rejection, Kidney Transplant Infection, Kidney Transplant; Complications, Kidney Disease, Chronic, Kidney Ischemia
Interventions
AlloSure, PAXGene
Diagnostic Test
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
glecaprevir/pibrentasvir treatment
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced May 22, 2026, 3:51 AM EDT
Conditions
BK Virus Infection
Interventions
Everolimus, Mycophenolic acid dose reduction
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2016 · Synced May 22, 2026, 3:51 AM EDT
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
300mg glecaprevir/pibrentasivir 120mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
Zepatier, Zepatier plus Sofosbuvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Mucositis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
supersaturated calcium phosphate rinse, placebo, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 21 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Arcadia, California • Duarte, California • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
etanercept, methylprednisolone
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Cancer
Interventions
polymorphism analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Hiv
Interventions
HIV D+/R+
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, thiotepa, topotecan hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support, in vitro-treated bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Cancer
Interventions
DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Urinary Tract Infection, Recurrent
Interventions
phage therapy, control
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Kidney Transplant Recipients, Liver Transplant Recipients
Interventions
Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 3:51 AM EDT
Conditions
BK Virus (BKV) Viremia
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced May 22, 2026, 3:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Kidney; Complications, Allograft, Transplantation Infection
Interventions
Immunosuppressive Agents
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
2 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced May 22, 2026, 3:51 AM EDT
Conditions
COVID-19, Kidney Transplant
Interventions
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced May 22, 2026, 3:51 AM EDT
Conditions
End-Stage Renal Disease, Hepatitis C
Interventions
Zepatier, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Kidney Transplant Recipients
Interventions
Varivax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
4
States / cities
Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced May 22, 2026, 3:51 AM EDT
Conditions
COVID-19, Immunosuppression, Vaccine Response Impaired
Interventions
Reduction in antimetabolite immunosuppression
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Kidney Transplant Dysfunction
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced May 22, 2026, 3:51 AM EDT
Conditions
Cancer
Interventions
acyclovir, acyclovir sodium, valacyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced May 22, 2026, 3:51 AM EDT